Serum levels of visfatin and possible interaction with iron parameters in gestational diabetes mellitus

Gynecol Obstet Invest. 2013;75(3):203-9. doi: 10.1159/000348560. Epub 2013 Mar 15.

Abstract

Background/aims: Visfatin is a novel adipokine with insulinomimetic properties that increases in diabetes. However, for gestational diabetes mellitus (GDM) there are conflicting reports. Recent studies have reported a positive association of serum ferritin concentrations with insulin resistance. Thus, we assessed serum levels of visfatin in pregnant women with varying degrees of glucose tolerance and investigated the possible interaction of visfatin with parameters of iron metabolism.

Methods: Visfatin levels were measured at 24-28 weeks of gestation in 88 women who were divided into three groups according to their response to a 50-gram glucose challenge test and a 100-gram oral glucose tolerance test: control group (n = 28), impaired glucose tolerance (IGT) group (n = 30) and GDM group (n = 30).

Results: Visfatin levels were significantly higher in the GDM and IGT group than in control (p < 0.001 for GDM vs. control, and p = 0.004 for IGT vs. control). Serum visfatin was significantly associated with serum ferritin, insulin, age, gravidity, and body mass index. In a linear regression model, the covariates explained only 17% of variability of serum visfatin concentration. Body mass index (p < 0.001) contributed independently to visfatin variance.

Conclusion: Serum visfatin concentration is significantly higher in GDM and is correlated with ferritin levels.

MeSH terms

  • Adult
  • Body Mass Index
  • Case-Control Studies
  • Diabetes, Gestational / blood*
  • Female
  • Ferritins / blood*
  • Glucose Intolerance / blood
  • Humans
  • Insulin Resistance
  • Linear Models
  • Nicotinamide Phosphoribosyltransferase / blood*
  • Pregnancy

Substances

  • Ferritins
  • Nicotinamide Phosphoribosyltransferase